• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Lev Pharmaceuticals

edit

Lev Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Its products include C1-INH that is used for the treatment of hereditary angioedema. The company was founded in 2003 and is based in New York, New York. As of October 21, 2008, Lev Pharmaceuticals, Inc. operates as a subsidiary of ViroPharma Inc.

Milestones

edit

• 
  Lev Pharmaceuticals added Douglas Beck as CFO.
  Posted 9/14/09 at 5:20pm
• 
  Lev Pharmaceuticals added Judson A. Cooper as Co-founder .
  Posted 9/14/09 at 5:20pm
• 
  Lev Pharmaceuticals added Joshua D. Schein as Co-founder .
  Posted 9/14/09 at 5:20pm
• 
  Lev Pharmaceuticals received $21M in Venture Round funding. (10/23/06)
  Posted 4/21/10 at 8:17pm via biospace.com
• 
  Lev Pharmaceuticals received $20M in Venture Round funding. (11/8/07)
  Posted 3/15/10 at 1:08am via findarticles.com
• 
  Lev Pharmaceuticals was acquired by ViroPharma for $586M. (7/15/08)
  Posted 9/14/09 at 5:29pm via fiercebiotech.com

Videos

Screenshots

edit

Sources

1. ViroPharma To Acquire Lev Pharmaceuticals (fiercebiotech.com) [edit]
2. Lev Pharmaceuticals, Inc. Announces $21 Million Private Placement (biospace.com) [edit]
3. Lev Pharmaceuticals Announces $20 Million Senior Secured Term Loan Facility (findarticles.com) [edit]